Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Small molecule combats cancer-causing KRAS protein at last.

Literature DB >> 31705127

Small molecule combats cancer-causing KRAS protein at last.

Roy S Herbst, Joseph Schlessinger.

Abstract

Entities: Chemical

Keywords: Cancer; Immunology; Medical research

Mesh：

Substances：

Year: 2019 PMID： 31705127 DOI： 10.1038/d41586-019-03242-8

Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962

× No keyword cloud information.

9 in total

1. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

Authors: Matthew P Patricelli; Matthew R Janes; Lian-Sheng Li; Rasmus Hansen; Ulf Peters; Linda V Kessler; Yuching Chen; Jeff M Kucharski; Jun Feng; Tess Ely; Jeffrey H Chen; Sarah J Firdaus; Anjali Babbar; Pingda Ren; Yi Liu
Journal: Cancer Discov Date: 2016-01-06 Impact factor: 39.397

Review 2. The biology and management of non-small cell lung cancer.

Authors: Roy S Herbst; Daniel Morgensztern; Chris Boshoff
Journal: Nature Date: 2018-01-24 Impact factor: 49.962

3. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.

Authors: Matthew R Janes; Jingchuan Zhang; Lian-Sheng Li; Rasmus Hansen; Ulf Peters; Xin Guo; Yuching Chen; Anjali Babbar; Sarah J Firdaus; Levan Darjania; Jun Feng; Jeffrey H Chen; Shuangwei Li; Shisheng Li; Yun O Long; Carol Thach; Yuan Liu; Ata Zarieh; Tess Ely; Jeff M Kucharski; Linda V Kessler; Tao Wu; Ke Yu; Yi Wang; Yvonne Yao; Xiaohu Deng; Patrick P Zarrinkar; Dirk Brehmer; Dashyant Dhanak; Matthew V Lorenzi; Dana Hu-Lowe; Matthew P Patricelli; Pingda Ren; Yi Liu
Journal: Cell Date: 2018-01-25 Impact factor: 41.582

4. AACR Project GENIE: Powering Precision Medicine through an International Consortium.

Authors:
Journal: Cancer Discov Date: 2017-06-01 Impact factor: 39.397

5. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

Authors: Jude Canon; Karen Rex; Anne Y Saiki; Christopher Mohr; Keegan Cooke; Dhanashri Bagal; Kevin Gaida; Tyler Holt; Charles G Knutson; Neelima Koppada; Brian A Lanman; Jonathan Werner; Aaron S Rapaport; Tisha San Miguel; Roberto Ortiz; Tao Osgood; Ji-Rong Sun; Xiaochun Zhu; John D McCarter; Laurie P Volak; Brett E Houk; Marwan G Fakih; Bert H O'Neil; Timothy J Price; Gerald S Falchook; Jayesh Desai; James Kuo; Ramaswamy Govindan; David S Hong; Wenjun Ouyang; Haby Henary; Tara Arvedson; Victor J Cee; J Russell Lipford
Journal: Nature Date: 2019-10-30 Impact factor: 49.962

6. Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Authors: Francisco Sanchez-Vega; Marco Mina; Joshua Armenia; Walid K Chatila; Augustin Luna; Konnor C La; Sofia Dimitriadoy; David L Liu; Havish S Kantheti; Sadegh Saghafinia; Debyani Chakravarty; Foysal Daian; Qingsong Gao; Matthew H Bailey; Wen-Wei Liang; Steven M Foltz; Ilya Shmulevich; Li Ding; Zachary Heins; Angelica Ochoa; Benjamin Gross; Jianjiong Gao; Hongxin Zhang; Ritika Kundra; Cyriac Kandoth; Istemi Bahceci; Leonard Dervishi; Ugur Dogrusoz; Wanding Zhou; Hui Shen; Peter W Laird; Gregory P Way; Casey S Greene; Han Liang; Yonghong Xiao; Chen Wang; Antonio Iavarone; Alice H Berger; Trever G Bivona; Alexander J Lazar; Gary D Hammer; Thomas Giordano; Lawrence N Kwong; Grant McArthur; Chenfei Huang; Aaron D Tward; Mitchell J Frederick; Frank McCormick; Matthew Meyerson; Eliezer M Van Allen; Andrew D Cherniack; Giovanni Ciriello; Chris Sander; Nikolaus Schultz
Journal: Cell Date: 2018-04-05 Impact factor: 41.582

7. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Authors: Jonathan M Ostrem; Ulf Peters; Martin L Sos; James A Wells; Kevan M Shokat
Journal: Nature Date: 2013-11-20 Impact factor: 49.962

8. The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.

Authors: Shaoyong Lu; Hyunbum Jang; Ruth Nussinov; Jian Zhang
Journal: Sci Rep Date: 2016-02-23 Impact factor: 4.379

9. The KRAS^G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Authors: Jill Hallin; Lars D Engstrom; Lauren Hargis; Andrew Calinisan; Ruth Aranda; David M Briere; Niranjan Sudhakar; Vickie Bowcut; Brian R Baer; Joshua A Ballard; Michael R Burkard; Jay B Fell; John P Fischer; Guy P Vigers; Yaohua Xue; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Karen Velastagui; Richard C Chao; Jeremy Barton; Mariaelena Pierobon; Elisa Baldelli; Emanuel F Patricoin; Douglas P Cassidy; Matthew A Marx; Igor I Rybkin; Melissa L Johnson; Sai-Hong Ignatius Ou; Piro Lito; Kyriakos P Papadopoulos; Pasi A Jänne; Peter Olson; James G Christensen
Journal: Cancer Discov Date: 2019-10-28 Impact factor: 38.272

9 in total

Review 1. Future perspectives from lung cancer pre-clinical models: new treatments are coming?

Authors: Francesca Bersani; Deborah Morena; Francesca Picca; Alessandro Morotti; Fabrizio Tabbò; Paolo Bironzo; Luisella Righi; Riccardo Taulli
Journal: Transl Lung Cancer Res Date: 2020-12

2. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.

Authors: Alberto Pavan; Andrea Boscolo Bragadin; Lorenzo Calvetti; Alessandra Ferro; Elisabetta Zulato; Ilaria Attili; Giorgia Nardo; Alessandro Dal Maso; Stefano Frega; Andrea Giovanni Menin; Matteo Fassan; Fiorella Calabrese; Giulia Pasello; Valentina Guarneri; Giuseppe Aprile; PierFranco Conte; Rafael Rosell; Stefano Indraccolo; Laura Bonanno
Journal: Transl Lung Cancer Res Date: 2021-01

Small molecule combats cancer-causing KRAS protein at last.

1. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.

Review 2. The biology and management of non-small cell lung cancer.

3. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.

4. AACR Project GENIE: Powering Precision Medicine through an International Consortium.

5. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.

6. Oncogenic Signaling Pathways in The Cancer Genome Atlas.

7. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

8. The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.

9. The KRAS^G12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Review 1. Future perspectives from lung cancer pre-clinical models: new treatments are coming?

2. Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.

3. KRAS gene polymorphisms are associated with the risk of glioma: a two-center case-control study.

4. Distinct roles of tumor associated mutations in collective cell migration.

Review 5. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.

6. Label-free cell tracking enables collective motion phenotyping in epithelial monolayers.

Review 7. Non-Coding RNAs in Lung Tumor Initiation and Progression.

Review 8. A Breakthrough Brought about by Targeting KRAS^G12C: Nonconformity Is Punished.

Review 9. The Research Progress of Direct KRAS G12C Mutation Inhibitors.

Review 2. The biology and management of non-small cell lung cancer.

Review 1. Future perspectives from lung cancer pre-clinical models: new treatments are coming?

Review 5. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.

Review 7. Non-Coding RNAs in Lung Tumor Initiation and Progression.

Review 8. A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished.

Review 9. The Research Progress of Direct KRAS G12C Mutation Inhibitors.

Review 8. A Breakthrough Brought about by Targeting KRAS^G12C: Nonconformity Is Punished.